Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:GEVA
- CUSIP: 87159A10
- Web: www.synageva.com
Average Prices:- 50 Day Moving Avg: $215.15
- 200 Day Moving Avg: $131.31
- 52 Week Range: $60.19 - $239.20
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -36.04
- P/E Growth: 0.00
Profitability:- Net Margins: -6,429.45%
- Return on Equity: -39.57%
- Return on Assets: -37.57%
Misc:- Average Volume: 895,402 shs.
Frequently Asked Questions for Synageva Biopharma Corp (NASDAQ:GEVA)
What is Synageva Biopharma Corp's stock symbol?
Synageva Biopharma Corp trades on the NASDAQ under the ticker symbol "GEVA."
How were Synageva Biopharma Corp's earnings last quarter?
Synageva Biopharma Corp (NASDAQ:GEVA) issued its quarterly earnings results on Thursday, February, 26th. The company reported ($1.73) EPS for the quarter, missing the Zacks' consensus estimate of ($1.71) by $0.02. The business had revenue of $1.24 million for the quarter, compared to analysts' expectations of $1.25 million. Synageva Biopharma Corp had a negative net margin of 6,429.45% and a negative return on equity of 39.57%. View Synageva Biopharma Corp's Earnings History.
Who are some of Synageva Biopharma Corp's key competitors?
Some companies that are related to Synageva Biopharma Corp include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), ICON PLC (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), PAREXEL International Corporation (PRXL), Exact Sciences Corporation (EXAS), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD) and Nektar Therapeutics (NKTR).
How do I buy Synageva Biopharma Corp stock?
Shares of Synageva Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synageva Biopharma Corp's stock price today?
One share of Synageva Biopharma Corp stock can currently be purchased for approximately $238.60.
MarketBeat Community Rating for Synageva Biopharma Corp (NASDAQ GEVA)MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Synageva Biopharma Corp (NASDAQ:GEVA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Synageva Biopharma Corp (NASDAQ:GEVA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/28/2016 | Wedbush | Boost Price Target | Neutral | $67.00 -> $93.00 | N/A |  |
(Data available from 7/27/2015 forward)
Earnings History for Synageva Biopharma Corp (NASDAQ:GEVA)Earnings History by Quarter for Synageva Biopharma Corp (NASDAQ GEVA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/26/2015 | Q114 | ($1.71) | ($1.73) | $1.25 million | $1.24 million | View | Listen | |
| 10/30/2014 | Q3 2014 | ($1.61) | ($1.46) | $1.40 million | $1.33 million | View | N/A | |
| 7/30/2014 | Q2 2014 | ($1.37) | ($1.52) | $1.43 million | $2.34 million | View | N/A | |
| 4/30/2014 | Q1 2014 | ($1.19) | ($1.16) | $1.86 million | $1.59 million | View | N/A | |
| 3/3/2014 | Q4 13 | ($1.02) | ($1.00) | $4.88 million | $3.47 million | View | N/A | |
| 8/5/2013 | Q2 2013 | ($0.76) | ($0.81) | $2.90 million | $3.41 million | View | N/A | |
| 3/11/2013 | Q4 2012 | ($0.60) | ($0.62) | $2.32 million | $2.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Synageva Biopharma Corp (NASDAQ:GEVA)Current Year EPS Consensus Estimate: $-7.33 EPS
Next Year EPS Consensus Estimate: $-6.62 EPS
Dividend History for Synageva Biopharma Corp (NASDAQ:GEVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Synageva Biopharma Corp (NASDAQ:GEVA)Insider Trades by Quarter for Synageva Biopharma Corp (NASDAQ:GEVA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/8/2015 | Glen Williams | SVP | Sell | 12,916 | $214.92 | $2,775,906.72 | |
| 4/27/2015 | Anthony Quinn | CMO | Sell | 10,000 | $110.00 | $1,100,000.00 | |
| 4/21/2015 | Anthony Quinn | CMO | Sell | 10,000 | $108.00 | $1,080,000.00 | |
| 4/15/2015 | Anthony Quinn | CMO | Sell | 10,000 | $105.00 | $1,050,000.00 | |
| 4/8/2015 | Glen Williams | SVP | Sell | 42,632 | $96.08 | $4,096,082.56 | |
| 4/6/2015 | Anthony Quinn | CMO | Sell | 29,503 | $93.76 | $2,766,201.28 | |
| 1/7/2015 | Julian Baker | Director | Buy | 1,000,000 | $94.19 | $94,190,000.00 | |
| 12/29/2014 | Chris Heberlig | VP | Sell | 6,100 | $91.14 | $555,954.00 | |
| 12/17/2014 | Sanj K Patel | CEO | Sell | 50,000 | $88.85 | $4,442,500.00 | |
| 10/30/2014 | Carsten Boess | CFO | Sell | 25,404 | $80.10 | $2,034,860.40 | |
| 9/19/2014 | Mark Alan Goldberg | EVP | Sell | 790 | $65.24 | $51,539.60 | |
| 9/17/2014 | Mark Alan Goldberg | EVP | Sell | 13,579 | $65.03 | $883,042.37 | |
| 9/2/2014 | Anthony Quinn | CMO | Sell | 10,000 | $70.14 | $701,400.00 | |
| 6/20/2014 | Barry D Quart | Director | Sell | 1,375 | $100.00 | $137,500.00 | |
| 6/17/2014 | Barry D Quart | Director | Sell | 1,000 | $90.00 | $90,000.00 | |
| 6/12/2014 | Barry D Quart | Director | Sell | 1,000 | $83.31 | $83,310.00 | |
| 6/11/2014 | Mark Alan Goldberg | EVP | Sell | 21,597 | $80.00 | $1,727,760.00 | |
| 5/16/2014 | Carsten Boess | CFO | Sell | 9,927 | $81.94 | $813,418.38 | |
| 4/1/2014 | Anthony Quinn | CMO | Sell | 20,000 | $83.53 | $1,670,600.00 | |
| 3/12/2014 | Chris Heberlig | VP | Sell | 7,670 | $98.56 | $755,955.20 | |
| 3/6/2014 | Felix Baker | Director | Buy | 375,000 | $105.75 | $39,656,250.00 | |
| 1/29/2014 | Sanj Patel | CEO | Sell | 102,300 | $88.12 | $9,014,676.00 | |
| 12/3/2013 | Mark Alan Goldberg | SVP | Sell | 7,000 | $60.52 | $423,640.00 | |
| 11/1/2013 | Mark Alan Goldberg | SVP | Sell | 7,000 | $49.96 | $349,720.00 | |
| 9/25/2013 | Julian Baker | Director | Buy | 1,050,000 | $56.63 | $59,461,500.00 | |
| 8/21/2013 | Carsten Boess | CFO | Sell | 14,481 | $47.11 | $682,199.91 | |
| 8/16/2013 | Carsten Boess | CFO | Sell | 4,300 | $47.47 | $204,121.00 | |
| 7/29/2013 | Sanj K Patel | CEO | Sell | 100,000 | $48.02 | $4,802,000.00 | |
| 7/16/2013 | Chris Heberlig | VP | Sell | 2,524 | $48.43 | $122,237.32 | |
| 7/11/2013 | Carsten Boess | CFO | Sell | 13,237 | $47.06 | $622,933.22 | |
| 6/12/2013 | Sanj K Patel | CEO | Sell | 70,000 | $40.65 | $2,845,500.00 | |
| 2/1/2013 | Mark Alan Goldberg | SVP | Sell | 4,417 | $47.75 | $210,911.75 | |
| 1/17/2013 | Anthony Quinn | SVP | Sell | 5,553 | $50.07 | $278,038.71 | |
| 1/16/2013 | Carsten Boess | CFO | Sell | 9,927 | $49.12 | $487,614.24 | |
| 1/9/2013 | Thomas J Tisch | Director | Buy | 21,039 | $47.53 | $999,983.67 | |
| 1/4/2013 | Julian Baker | Director | Buy | 859,720 | $47.53 | $40,862,491.60 | |
| 9/4/2012 | Chris Heberlig | VP | Sell | 1,000 | $49.10 | $49,100.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Synageva Biopharma Corp (NASDAQ:GEVA)
Latest Headlines for Synageva Biopharma Corp (NASDAQ:GEVA)
| Source: |
|
Synageva Biopharma Corp (GEVA) Chart for Thursday, July, 27, 2017
